European Commission: Health systems to avoid the need for real-world data

Ways to reduce their costs, but without reducing the effectiveness of their services and the effectiveness of the treatment, looking for health care systems worldwide

In achieving this goal, the bidding data is contributed to the major national database with medical information, so that they can conclude the disease and get the result of their treatment.

If statistical analysis, processing and exploitation of these data was made in a general European framework (either through cooperation between the choristers or universities and research centers), its profit can not be denied, because the existing medical data Can be changed (physicians are personalized more effective), but avoid unnecessary costs.

This was a central topic of discussion at the European Commission Conference on the treatment and research of Multiple Sclerosis (ECTRIMS 2017) in Paris, where the value of 'real world figures' was already a topic of exploitation abroad.

Real-world figures have data using real-time new medical or health technologies, and according to scientists, they can give a more realistic picture of both therapeutic effects and their economic profile. The reason for this is that from the real world data, scientists can obtain information about a group of patients whose diagnosis is not represented with clinical trials or co-patient etc.

If real-world data is mixed with the results of the laboratory and clinical studies, they can ultimately lead to personal therapies which are more influenced by the impact of health systems and the economy. They are also useful for regulators, because they collect more information about side effects. In fact, as stated in ECTRIMS 2017, cooperative member states will try to work with states to ensure that national health care systems opt for the best treatment for patients with multiple sclerosis, thus eliminating waste of public money. Reduces and helps patients to avoid unwanted effects.

Logically, the source of real-world data is patient registrations, although they have been implemented in Europe, there is no complete patient register for Hepatitis C in Greece so far. In addition, in the initial stage we are working with the electronic patient folder, while data from the successful implementation of electronic prescriptions, which have the potential to deliver real-world data, are largely unemployed.